Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EBIT (2018 - 2025)

Historic EBIT for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$7.4 million.

  • Inmune Bio's EBIT rose 3950.02% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.4 million, marking a year-over-year decrease of 2365.75%. This contributed to the annual value of -$42.6 million for FY2024, which is 4335.43% down from last year.
  • Per Inmune Bio's latest filing, its EBIT stood at -$7.4 million for Q3 2025, which was up 3950.02% from -$24.6 million recorded in Q2 2025.
  • Inmune Bio's 5-year EBIT high stood at -$4.5 million for Q1 2021, and its period low was -$24.6 million during Q2 2025.
  • In the last 5 years, Inmune Bio's EBIT had a median value of -$8.4 million in 2023 and averaged -$8.9 million.
  • Examining YoY changes over the last 5 years, Inmune Bio's EBIT showed a top increase of 3950.02% in 2025 and a maximum decrease of 14907.25% in 2025.
  • Quarter analysis of 5 years shows Inmune Bio's EBIT stood at -$9.0 million in 2021, then soared by 37.52% to -$5.6 million in 2022, then tumbled by 48.51% to -$8.4 million in 2023, then fell by 12.98% to -$9.5 million in 2024, then grew by 21.49% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q3 2025, -$24.6 million for Q2 2025, and -$9.9 million during Q1 2025.